References of "Annales d'Endocrinologie"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailUne néoplasie endocrinienne multiple particulière
Boccar, S; VROONEN, Laurent ULiege; HAMOIR, Etienne ULiege et al

in Annales d'Endocrinologie (2013, October), 74

Detailed reference viewed: 29 (1 ULiège)
Full Text
Peer Reviewed
See detailHypercalcémie réfractaire et sécrétion ectopique de calcitonine dans un cancer neuroendocrine du pancréas : Effets hypocalcémiants du Cinacalcet
VALDES SOCIN, Hernan Gonzalo ULiege; LOLY, Jean-Philippe ULiege; BETEA, Daniela ULiege et al

in Annales d'Endocrinologie (2013, September), 74(4), 235-462

Introduction: Paraneoplastic hypercalcemia is a sign of poor prognosis, as it is particularly resistant to the usual hypocalcemic treatments. Observation: In 2009, a well differentiated pancreatic ... [more ▼]

Introduction: Paraneoplastic hypercalcemia is a sign of poor prognosis, as it is particularly resistant to the usual hypocalcemic treatments. Observation: In 2009, a well differentiated pancreatic neuroendocrine tumor (Ki-67= 2%) is diagnosed in a 52-year-old diabetic man. The tumor is revealed with a splenic and hepatic carcinomatosis. Plasmatic calcium was: 3.54 mmol/L (2.15 - 2.6). Biology showed hypophosphatemia, PTH < 4 ng/ml, high 1-25 OH VitD, calcitonin: 1016 ng/ml (< 12 ng/ml). He had hypercalciuria and hypophosphaturia. He received for two years several cycles of Streptozotocin-ADRIAMYCIN and FOLFOX, with partial control of the tumor mass and calcium levels. In 2012, calcitonin levels are 29 ng/ml whereas calcemia is 3.17 mmol/L. Hypercalcemia is refractory to hyperhydration, diuretics, corticosteroids, and bisphosphonates therapy. Cinacalcet (Mimpara) is prescribed up to 120 mg/day (PO). Calcemia decreases gradually from 3 to 2.87 and then 2.76 mmol/L. PTH and calcitonin-the tumor mass remain unchanged. After two months of Cinacalcet treatment, Sunitinib (Sutent) 37.5 mg per day was added. During the third month, calcium levels dropped to 2.09 mmol/L and PTH raised to 78 pg/ml, requiring discontinuation of Mimpara. Calcitonin normalized, with a further improvement over pancreatic and metastatic lesions. Conclusion: Cinacalcet is a Calcium Sensing Receptor oral agonist. Cinacalcet hypocalcemic effects have not been previously documented in pancreatic paraneoplastic hypercalcemia. In our patient, Cinacalcet has significantly improved cancer prognosis: this drug could be a new alternative in paraneoplastic hypercalcemia. [less ▲]

Detailed reference viewed: 128 (9 ULiège)
Full Text
Peer Reviewed
See detailGLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?
SCHEEN, André ULiege

in Annales d'Endocrinologie (2013)

Pharmacological treatment of type 2 diabetes has been enriched during recent years, with the launch of incretin therapies targeting glucagon-like peptide-1 (GLP-1). Such medications comprise either GLP-1 ... [more ▼]

Pharmacological treatment of type 2 diabetes has been enriched during recent years, with the launch of incretin therapies targeting glucagon-like peptide-1 (GLP-1). Such medications comprise either GLP-1 receptor agonists, with short (one or two daily injections: exenatide, liraglutide, lixisenatide) or long duration (one injection once weekly: extended-released exenatide, albiglutide, dulaglutide, taspoglutide); or oral compounds inhibiting dipeptidyl peptidase-4 (DPP-4), the enzyme that inactives GLP-1, also called gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin). Although both pharmacological approaches target GLP-1, important differences exist concerning the mode of administration (subcutaneous injection versus oral ingestion), the efficacy (better with GLP-1 agonists), the effects on body weight and systolic blood pressure (diminution with agonists versus neutrality with gliptins), the tolerance profile (nausea and possibly vomiting with agonists) and the cost (higher with GLP-1 receptor agonists). Both agents may exert favourable cardiovascular effects. Gliptins may represent a valuable alternative to a sulfonylurea or a glitazone after failure of monotherapy with metformin while GLP-1 receptor agonists may be considered as a good alternative to insulin (especially in obese patients) after failure of a dual oral therapy. However, this scheme is probably too restrictive and modalities of using incretins are numerous, in almost all stages of type 2 diabetes. Physicians may guide the pharmacological choice based on clinical characteristics, therapeutic goals and patient's preference. [less ▲]

Detailed reference viewed: 126 (1 ULiège)
Full Text
Peer Reviewed
See detailQuels benefices antitumoraux attendre de la metformine ?
Beck, Emmanuel; SCHEEN, André ULiege

in Annales d'Endocrinologie (2013), 74(2), 137-47

With the better management of cardiovascular risk factors, cancer plays an increasing role in the causes of death among patients with type 2 diabetes. Numerous epidemiological cohort and case-control ... [more ▼]

With the better management of cardiovascular risk factors, cancer plays an increasing role in the causes of death among patients with type 2 diabetes. Numerous epidemiological cohort and case-control studies showed that type 2 diabetes is a risk factor for cancer and that metformin therapy is associated with a significant reduction in the incidence of cancer and cancer-related death when compared to other glucose-lowering agents (sulfonylureas, insulin). Such beneficial effect is observed almost whatever the type of cancer, but seems to be more prominent in case of gastrointestinal and breast cancers. Several studies showed a significant relationship between the amplitude of the protection against cancer, on the one hand, and the daily dose of metformin and the duration of exposure, on the other hand. In general, the protective effect was more evident in observational cohort studies (however, more exposed to bias due to confounding factors) than in case-control studies. Several meta-analyses recently confirmed that metformin therapy reduces the incidence of cancers and cancer-related mortality. However, the results of the rather rare controlled clinical trials available are not conclusive, but none of them was performed with the objective to specifically assess cancer risk. Considering all promising clinical information in patients with type 2 diabetes, further clinical trials are currently ongoing with the aim of assessing the role of metformin in oncology, independently of the presence of diabetes. [less ▲]

Detailed reference viewed: 39 (1 ULiège)
Full Text
Peer Reviewed
See detailVitamin D and primary hyperparathyroidism (PHPT)
Souberbielle, Jean-Claude; Bienaimé, Frank; CAVALIER, Etienne ULiege et al

in Annales d'Endocrinologie (2012), 73(3), 165-169

Vitamin D deficiency and primary hyperparathyroidism (PHPT) are two common conditions, especially in postmenopausal women. Vitamin D deficiency is said to be even more frequent in PHPT patients than in ... [more ▼]

Vitamin D deficiency and primary hyperparathyroidism (PHPT) are two common conditions, especially in postmenopausal women. Vitamin D deficiency is said to be even more frequent in PHPT patients than in the general population due to an accelerated conversion of 25-hydroxy vitamin D (25OHD) into calcitriol or 24-hydroxylated compounds. Although several studies have reported worsening of PHPT phenotype (larger tumours, higher parathyroid hormone [PTH] levels, more severe bone disease) when vitamin D deficiency coexists whereas vitamin D supplementation in PHPT patients with a serum calcium level less than 3 mmol/L has been shown to be safe (no increase in serum or urinary calcium) and to decrease serum PTH concentration, many physicians are afraid to give vitamin D to already hypercalcemic PHPT patients. It is possible that, in some patients, a persistent vitamin D deficiency induces, in the long-term, an autonomous secretion of PTH (i.e. tertiary hyperparathyroidism). The mechanism by which this could occur is unclear however. Finally, as many, otherwise normal, subjects with vitamin D insufficiency may have an increased serum PTH level we believe that those with vitamin D insufficiency should be excluded from a reference population for serum PTH levels. By doing that, we found that the upper normal limit for serum PTH was 25–30% lower than in the whole population. [less ▲]

Detailed reference viewed: 29 (0 ULiège)
Full Text
Peer Reviewed
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULiege; Jaffrain Rea, ML; PETROSSIANS, Patrick ULiege et al

in Annales d'Endocrinologie (2012, April), 73(2), 153

Detailed reference viewed: 41 (4 ULiège)
Full Text
Peer Reviewed
See detailA prospective study of cardiac valvular status in patients treated with cabergoline for Endocrine Disease
VROONEN, Laurent ULiege; Lancellotti, Patrizio ULiege; Tome Garcia, M et al

in Annales d'Endocrinologie (2012, April), 73(2), 148

Detailed reference viewed: 27 (4 ULiège)
Full Text
Peer Reviewed
See detailOverview of genetic testing in patients with pituitary adenomas
Beckers, Albert ULiege; Rostomyan, Liliya ULiege; Daly, Adrian ULiege

in Annales d'Endocrinologie (2012), 73

Detailed reference viewed: 19 (2 ULiège)
Full Text
Peer Reviewed
See detailThe Liege Acromegaly Survey (LAS) : A new software tool for the study of acromegaly
PETROSSIANS, Patrick ULiege; Tichomirowa, M; Stevenaert, Achille ULiege et al

in Annales d'Endocrinologie (2012), 73

Detailed reference viewed: 61 (8 ULiège)
Full Text
Peer Reviewed
See detailAcromégalie et apnées du sommeil : évaluations céphalométriques
BRUWIER, Annick ULiege; Albert, Adelin ULiege; Beckers, Albert ULiege et al

in Annales d'Endocrinologie (2011)

Detailed reference viewed: 88 (13 ULiège)
Full Text
Peer Reviewed
See detailPrévalence et incidence d'épilepsie chez 270 patients avec un traumatisme crânien (TBI) et traités par GH, suivis dans KIMS
Valdes Socin, Hernan Gonzalo ULiege; Mattsson, A.; Koltowska-Haggstrom, M. et al

in Annales d'Endocrinologie (2010, September), 71(5), 396

Detailed reference viewed: 22 (0 ULiège)
Full Text
Peer Reviewed
See detailHypogonadisme congénital chez un homme, associé à une LK immunoréactive normale, élévation de FSH et azoospermie
Valdes Socin, Hernan Gonzalo ULiege; Chachati, Anne-Sophie ULiege; De Roux, N. et al

in Annales d'Endocrinologie (2010, September), 71(5), 355

Detailed reference viewed: 33 (5 ULiège)
Full Text
Peer Reviewed
See detailMutations AIP chez les jeunes patients en dessous de 30 ans avec adénome hypophysaire agressif
Beckers, Albert ULiege; Tichomirowa, M.; Barlier, A. et al

in Annales d'Endocrinologie (2010, September), 71(5), 397

Detailed reference viewed: 29 (4 ULiège)
Full Text
Peer Reviewed
See detailDeux nouvelles mutations dans le gène du récepteur du calcium (CASR) entraînant respectivement une hypo- et une hypercalcémie
Thonnard, Anne-Sophie ULiege; Livadariu, Elena ULiege; Rydlewski, C. et al

in Annales d'Endocrinologie (2010, September), 71(5), 367

Detailed reference viewed: 37 (7 ULiège)
Full Text
Peer Reviewed
See detailDosage de la vitamine D : attention aux erreurs analytiques!
Cavalier, Etienne ULiege; Carlisi, A.; Delanaye, Pierre ULiege et al

in Annales d'Endocrinologie (2010, September), 71(5), 368

Detailed reference viewed: 37 (4 ULiège)
Full Text
Peer Reviewed
See detailRésistance au traitement par GnRH agonistes dans le cancer de la prostate métastatique
Valdes Socin, Hernan Gonzalo ULiege; Waltregny, David ULiege; Beckers, Albert ULiege

in Annales d'Endocrinologie (2010, September), 71(5), 396

Detailed reference viewed: 20 (2 ULiège)
Full Text
Peer Reviewed
See detailKisspeptin-10 élevée chez les hommes obèses hypogonadiques - un nouveau signal périphérique entre le métabolisme et la reproduction
Valdes Socin, Hernan Gonzalo ULiege; Cavalier, Etienne ULiege; Beckaert, A. et al

in Annales d'Endocrinologie (2010, September), 71(5), 355

Detailed reference viewed: 23 (1 ULiège)
Full Text
Peer Reviewed
See detailUn nouveau marqueur tumoral pour le carcinome parathyroïdien? Résultats observés chez 24 patients
Cavalier, Etienne ULiege; Daly, Adrian ULiege; Betea, Daniela ULiege et al

in Annales d'Endocrinologie (2010, September), 71(5), 350-351

Detailed reference viewed: 33 (1 ULiège)